Aerococcus Urinae Endocarditis: A Case Report and Literature Review

Khalid Saeed Al-Asad, Naveed Mazhar, Shaurya Srivastava, Syed Quadri, Subhashis Mitra

Introduction

Infective endocarditis (IE) has classically been defined as an infection of the endocardial surface of the heart, the heart valves, or an indwelling cardiac device [1]. The annual incidence of endocarditis is increasing and has approached 15 cases per 100,000-person population as of 2011 [2]. Prompt diagnosis of infective endocarditis is essential, as it remains a highly morbid disease with a mortality rate of 20% at 50 days despite the wide array of antimicrobial treatments and surgical interventions that are now available [3]. Furthermore, a delay in diagnosis and treatment can lead to additional complications such as heart failure, abscess formation, valve perforation, intracardiac fistula, formation, or the development of pericarditis. Staphylococcus aureus is the most common cause of endocarditis in the world (approximately 31% of all cases), followed by the Enterococcus family [4]. Aerococcus urinae, a gram-positive, catalase-negative, alpha-hemolytic coccus, was first reported as a causative agent of IE in 1976 [5]. Our case of Aerococcus urinae IE was complicated by aortic valve leaflet perforation leading to severe aortic regurgitation and death. This case highlights the importance and necessity of the prompt diagnosis and treatment of infective endocarditis and makes the reader aware of uncommon and rare organisms, such as Aerococcus urinae, as potential etiologies.

Case Presentation

A 75-year-old Caucasian male presented to the emergency department of Sparrow Hospital, Lansing, Michigan with complaints of fever, chills, malaise, and fatigue for three days prior to presentation. His past medical history was significant for hypertension, hyperlipidemia, gastroesophageal reflux disease, stage T1c prostate cancer (Gleason 4+5) status post-robotic-assisted laparoscopic radical prostatectomy (RALP) in 2019, and the subsequent development of bladder neck contractures requiring transurethral incisions. Approximately two weeks prior to presentation, the patient was admitted with acute kidney injury, fever, dysuria, and urinary frequency. A CT scan of the abdomen and pelvis demonstrated a moderately distended bladder with marked bilateral hydronephrosis and hydrourerter. A Foley was placed for treatment of acute obstructive uropathy and the patient was treated with IV ceftriaxone 1000 mg for four days. His urine culture was negative for any bacterial growth and thus antibiotics were discontinued. Repeat renal ultrasound showed improved moderate hydronephrosis. The patient was deemed stable for discharge with a Foley catheter.

His vital signs upon presentation included a temperature of 101.9 ° F, heart rate of 118 beats per minute, respiratory rate of 17, and oxygen saturation of 98% on room air. Physical examination was remarkable for a diastolic rumble best heard at the right sternal border. A complete blood count and comprehensive metabolic panel were drawn and were remarkable for an elevated white blood cell count and an elevation in serum creatinine. Urinalysis was also suggestive of a urinary tract infection with elevated WBC. He was started on piperacillin-tazobactam for gram-negative and anaerobic coverage with urine and blood cultures being drawn. He had repeat imaging with a CT abdomen and pelvis showing improvement in prior hydronephrosis, new small pericardial effusion, and bladder wall thickening and prominence. Over the course of two days, the patient’s clinical course improved. Urine cultures grew Enterococcus faecalis and...
Alcaligenes faecalis (Table 1) while blood cultures grew Aerococcus urinae (Table 2).

|                | Enterococcus faecalis | Alcaligenes faecalis |
|----------------|-----------------------|----------------------|
| Ampicillin     | 1 ug/mL Susceptible   |                      |
| Cefepime       |                       | 4 ug/mL Susceptible  |
| Ceftazidime    |                       | <=2 ug/mL Susceptible|
| Ciprofloxacin  |                       | 2 ug/mL Intermediate |
| Gentamicin     |                       | 4 ug/mL Susceptible  |
| Levofloxacin   | <=1 ug/mL Susceptible | <=0.5 ug/mL Susceptible|
| Linezolid      | <=1 ug/mL Susceptible |                      |
| Nitrofurantoin | <=16 ug/mL Susceptible|                     |
| Piperacillin/Tazo |                   | <=2/4 ug/mL Susceptible|
| Tetracycline   | <=0.5 ug/mL Susceptible|                  |
| Tobramycin     | <=2 ug/mL Susceptible |                      |
| Trimeth/Sulfa  | <=0.5/9.5 ug/mL Susceptible|             |
| Vancomycin     | 2 ug/mL Susceptible   |                      |

**TABLE 1: Urine cultures and antibiogram**

| Aerococcus urinae | Bacterial Susceptibility Panel |
|-------------------|--------------------------------|
| Ceftriaxone       | 1 ug/mL                        | Susceptible                  |
| Levofloxacin      | 0.25 ug/mL                     | Susceptible                  |
| Meropenem         | 0.03 ug/mL                     | Susceptible                  |
| Penicillin        | 0.06 ug/mL                     | Susceptible                  |
| Vancomycin        | 0.5 ug/mL                      | Susceptible                  |

**TABLE 2: Blood cultures and antibiograms**

Both blood cultures grew Aerococcus urinae with the same antibiograms for both sets; to prevent redundancy, we have shown results from one.

TTE showed a sclerotic aortic valve with ill-defined abnormal echo densities, suggesting possible endocarditis. A transesophageal echo (TEE) showed perforation of all three aortic valve leaflets with severe regurgitation on color flow Doppler, with multiple echo densities (Figure 1).
Antibiotics were switched to IV penicillin G and IV gentamicin. Within the span of 12 hours from this result, the patient’s clinical course acutely deteriorated, with the development of severe respiratory distress with tachypnea (respiratory rate 30 breaths per minute), hypotension (blood pressure was 96/35 mmHg), and sinus tachycardia (heart rate 125 beats per minute). The patient was emergently taken to the operating room (OR) for open heart surgery for aortic valve replacement. En route to the OR, the patient had a cardiac arrest with pulseless electrical activity noted. Return of spontaneous circulation (ROSC) was achieved after 30 minutes, and a decision was made to abort surgery and transfer the patient to ICU. Within 30 min of arrival to the ICU unit, the patient had another cardiac arrest with pulseless electrical activity noted. The patient’s spouse made the decision to switch the patient to comfort care measures.

Discussion
Infective endocarditis (IE) can present in days (acute) or weeks to months (subacute). Acute IE is most commonly seen with S. aureus. Subacute IE can be due to both pathogenic and non-pathogenic bacteria that usually colonize an already damaged valve. Fever in the presence of new-onset murmur, Osler’s nodes, and Janeway lesions can be present [6]. Duke criteria for IE contain major and minor criteria. The major criteria are positive two separate blood cultures and an echocardiogram demonstrating evidence of vegetation. Minor criteria include fever, predisposing factors, vascular phenomena, immunological phenomena, and microbiological evidence. Patients at risk of IE are those that meet one major and minor criteria or three minor criteria [7]. Most patients receive four to six weeks of antibiotics for treatment. Surgical intervention is recommended in case of vegetation resolution being refractory to antibiotics, embolism during the first two weeks of antimicrobial therapy, vegetation after embolization, anterior mitral valve vegetation > 10 mm in size, development of new heart block, abscess formation, aortic or mitral valve dysfunction with ventricular failure, perforation along the perivalvular area, or valvular dehiscence [8].

Aerococcus urinae is a gram-positive, microaerophilic, catalase-negative, alpha-hemolytic coccus that can grow in clusters and tetrads and has the ability to form biofilms [5]. Despite it being a common cause of urinary tract infection (UTI) in males of late age (> 65), urinalysis and urine cultures can still appear negative as demonstrated not only in our case but in literature as well. Other risk factors include prostate hyperplasia, urethral strictures, and urinary tract surgery [9]. There have been case reports of infective endocarditis due to Aerococcus urinae. Subacute IE with damage to mitral and aortic valves has also been reported. In vitro, susceptibility to penicillin, cefotaxime, ceftriaxone, meropenem, tetracycline, levofloxacin, rifampin, linezolid, and vancomycin has been reported [10].

In 2020, Ludhwani et al. documented a case of a 59-year-old male with Aerococcus urinae UTI who
developed aortic valve regurgitation in the setting of endocarditis. Blood cultures confirmed Aerococcus urinae bacteremia and TEE confirmed regurgitation. In this case, the patient received intravenous vancomycin and surgical aortic valve repair. Similarly, in 2019, Sous et al. documented a case of an 11-year-old boy with a history of an unrepaired ventricular septal defect. The patient had foul-smelling urine followed by fevers. Blood culture grew Aerococcus urinae. The patient initially received vancomycin then based on susceptibility results was switched to penicillin G and gentamicin. An echocardiogram showed partial closure of VSD possibly related to tricuspid valve vegetation. Subsequently, the patient developed a lobulated mycotic aneurysm of the pulmonary artery secondary to embolism from vegetation. He underwent a right lower lobectomy and completed a six-week Penicillin G course [3].

Similarly, in 2016, Kotkar et al. documented a case of a 54-year-old male who presented with myocardial infarction due to embolism of the right coronary artery. An echocardiogram revealed severe mitral and tricuspid valve regurgitation. Sternotomy revealed large vegetation on the posterior leaflet of the mitral valve with thickening of the anterior leaflet. The patient underwent an embolectomy and bypass with grafting. In this case, after the surgery, the patient was discharged on a six-week course of ampicillin [11].

In contrast to the individual cases mentioned previously, a prior comprehensive review of Aerococcus urinae infective endocarditis was completed by Yabes et al. in 2018, which compiled a tabulated report of 45 cases of Aerococcus urinae infective endocarditis [12, 13]. A subsequent literature search demonstrated seven additional cases of Aerococcus urinae infective endocarditis described in Tai et al., which has brought the total number of known cases to 50 (Table 3) [14]. The average age among these 50 cases was noted to be 71 years of age, with 80% of cases noted to be in male patients. Common risk factors were most noted to be those that involved the genitourinary system (UTI, benign prostatic hyperplasia (BPH), Foley catheters, etc.) compared to the presence of valvular disease on its own. Aortic Valve involvement on its own was noted to be present among 48% of cases while sole Mitral Valve involvement comprised 44% of cases. Approximately 8% of cases rarely involved more than one valve. Surgical intervention was rare and took place in 26% of the listed cases. This is likely due to patients having an unfavorable risk profile with their underlying comorbidities, and not meeting 2014 AHA/ACC Class 1 surgical indication guidelines for Management of Patients with Valvular Heart Disease as mentioned by Yabes et al. It should be noted that the updated 2020 AHA/ACC Class 1 surgical indication guidelines for Management of Patients with Valvular Heart Disease recommend early surgical intervention in cases of infective endocarditis complicated with destructive penetrating valvular lesions even prior to completion of a full therapeutic course of antibiotics, which was not present in the 2014 guidelines [15]. Furthermore, among the 13 out of 50 cases that did receive surgical intervention, only one case died, suggesting that early surgical intervention when indicated may improve mortality outcomes. Among the antibiotic regimens used, the most common treatment course involved approximately 72% of the 50 cases receiving beta-lactam therapy with an aminoglycoside for an average duration of approximately six weeks, which resulted in approximately 78% of patients treated in this manner surviving.

| Case No. | Age | Sex | Risk factors | Valve | Surgery | Antibiotic regimen | Duration | Embolization | Survival |
|----------|-----|-----|--------------|-------|---------|-------------------|----------|--------------|----------|
| 1        | 56  | F   | UTI          | Aortic/Mitral Valve | Y      | Lactam/Van        | 2 to 4 weeks | Y           | Y        |
| 2        | 54  | M   | UTI          | Mitral Valve        | Y      | Ampicillin        | 6 weeks   | Y           | Y        |
| 3        | 79  | F   | UTI          | Mitral Valve        | N      | Lactam            | 4 weeks   | Y           | Y        |
| 4        | 72  | F   | UTI          | Aortic Valve        | Y      | Ampicillin        | 4 weeks   | N           | Y        |
| 5        | 46  | M   | UTI          | Aortic/Mitral Valve | N      | Lactam            | 2 weeks   | Y           | N        |
| 6        | 80  | M   | UTI          | Mitral Valve        | Y      | Lactam/AG         | 4 weeks   | N           | Y        |
| 7        | 70  | M   | UTI          | Mitral Valve        | Y      | Lactam/AG         | 4 weeks   | N           | Y        |
| 8        | 69  | M   | Cystoscopy   | Aortic Valve        | N      | Lactam/AG         | 6 wks     | N           | Y        |
| 9        | 54  | M   | Phimosis     | Mitral Valve        | Y      | Lactam            | 6 wks     | Y           | Y        |
| 10       | 43  | M   | Hepatitis C  | Aortic Valve        | N      | Lactam/AG         | 5 days    | Y           | N        |
| 11       | 68  | M   | Indwelling Catheter | Aortic Valve | Y      | Lactam/AG         | 6/2 wks   | Y           | Y        |
| 12       | 80  | M   | Malignancy   | Aortic Valve        | Y      | Lactam            | 6 wks     | -           | Y        |
| 13       | 87  | M   | Malignancy   | Mitral Valve        | -      | Lactam/AG         | -         | N           | N        |
| 14       | 77  | M   | Liver Failure | Aortic Valve        | -      | Lactam/AG         | -         | N           | Y        |
| 15       | 83  | M   | Indwelling Catheter | Mitral Valve | -      | Lactam/AG         | -         | N           | Y        |
| 16       | 73  | M   | Suprapubic Catheter | Aortic Valve | -      | Lactam/AG         | -         | N           | N        |
|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 17 | 88 | F | Aortic Stenosis | Aortic Valve | - | Lactam/AG | - | N | Y |
| 18 | 43 | M | Indwelling Catheter | Mitral Valve | Y | Lactam/AG | 6wks | N | Y |
| 19 | 77 | M | BPH | Aortic Valve | N | Lactam/Van | - | Y | N |
| 20 | 68 | M | BPH | Mitral Valve | N | Lactam/AG; oral regimen | 3wks; unknown | N | Y |
| 21 | 75 | M | Cystoscopy | Aortic Valve | Y | Lactam/AG | 6wks | Y | Y |
| 22 | 89 | M | TURP | Mitral Valve | N | Lactam/AG | 6wks | Y | Y |
| 23 | 81 | M | UTI | Aortic Valve | N | Lactam/AG | 2wks/8days | N | N |
| 24 | 91 | M | Indwelling Catheter | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 25 | 91 | F | Inner Bladder Pressure | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 26 | 75 | M | BPH | Mitral Valve | N | Lactam/AG | 4wks/10days | N | Y |
| 27 | 86 | M | Urethral Stricture | Aortic Valve | N | Lactam/AG | 4wks/10days | Y | Y |
| 28 | 83 | M | Urethral Stricture | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 29 | 80 | F | - | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 30 | 77 | M | - | Aortic Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 31 | 75 | M | BPH | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 32 | 74 | M | Suprapubic Catheter | - | - | Lactam/AG | 4wks/10days | N | Y |
| 33 | 65 | M | Indwelling Catheter | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 34 | 53 | M | Dysuria | Aortic Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 35 | 49 | F | Intermittent catheter | Aortic Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 36 | 81 | M | Indwelling Catheter | Mitral Valve | - | Lactam/AG | 4wks/10days | N | Y |
| 37 | 74 | F | Malignancy | - | - | Lactam/AG | 4wks/10days | N | Y |
| 38 | 42 | M | None | Aortic Valve | Y | Lactam/AG | 6wks | Y | Y |
| 39 | 49 | M | - | Aortic Valve | - | Lactam/AG | - | N | Y |
| 40 | 54 | M | Urethral Stricture | Tricuspid/Aortic Valve | N | Lactam/AG | - | N | N |
| 41 | 69 | M | Malignancy | Aortic Valve | Y | Lactam | 12wks | N | Y |
| 42 | 62 | M | BPH | Mitral/Aortic Valve | Y | Lactam/Rif, AG | 6wks, AG 2wks | - | Y |
| 43 | 81 | M | BPH | Mitral Valve | N | Lactam/AG | 6wks | N | Y |
| 44 | 78 | M | Indwelling Catheter | Aortic Valve | N | Lactam | - | N | N |
| 45 | 87 | M | BPH | Mitral Valve | N | - | - | N | N |
| 46 | 78 | F | Ureteral Stent | Aortic Valve | N | Lactam/Van | 2wks | N | N |
| 47 | 48 | M | ASD | Mitral Valve | N | Lactam/AG | - | Y | Y |
| 48 | 79 | F | UTI | Aortic Valve | N | Lactam | 6wks | Y | Y |
| 49 | 78 | M | Aortic Stenosis | Aortic Valve | N | Lactam/AG | 10 days | - | N |
| 50 | 74 | M | BPH | Mitral Valve | Y | Lactam/AG | 4wks | Y | N |
| 51 | 79 | M | - | Aortic Valve | N | Van | 6wks | N | N |
| 52 | 67 | M | UTI/Prosthesis | Mitral Valve | Y | Lactam | 6wks | N | Y |
| 53 | 42 | M | Nephrolithiasis | Aortic/Mitral/Pulmonic Valve | N | - | - | Y | N |
| 54 | 92 | M | Valve regurgitation | Mitral/Tricuspid Valve | N | Lactam | 4wks | Y | Y |
| 55 | 61 | M | Indwelling Catheter | Aortic Valve | Y | Lactam/AG | 6wks | N | Y |
TABLE 5: Tabulated case reports of Aerococcus Urinae endocarditis.

|   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|
| 56 | 58 | M | Phèmosis | Aortic Valve | Y | Van | 6wks | Y | Y |
| 57 | 43 | M | UTI/Bioprosthetic valve | Aortic Valve | N | Lactam/Van | - | N | Y |
| 58 | 86 | F | Aortic stenosis | Aortic Valve | N | Lactam/AG | 6wks | N | N |

Data from: (Ludhwani, 2020) [3], (Yabes, 2018) [12], (Tai, 2021) [14], (Feghaly, 2022) [16], (Lattanzio, 2020) [17], (Bathania, 2019) [18], (Rosborough, 2020) [19], (Martin-Guerra, 2020) [20], (Ahmed, 2021) [21], (Varughese, 2021) [22], (Khan, 2021) [23]

Conclusions
This case of a 75-year-old male highlights the late manifestations of untreated Aerococcus urinae infective endocarditis, the importance of promptly diagnosing endocarditis with valvular involvement, and the need for immediate surgical evaluation. We have compiled an extensive review of 58 documented cases of Aerococcus urinae endocarditis, which currently accounts for all known documented cases at this time. While more studies are required to determine the optimal choice, therapy, and duration of antibiotics, the most recent 2020 American Heart Association (AHA)/American College of Cardiology (ACC) Class 1 surgical indication guidelines for the management of patients with valvular heart disease have clearly demonstrated the importance of immediate surgical evaluation even prior to the completion of antibiotic therapy. It is our hope that valvular evaluation in patients with Aerococcus bloodstream infections should be conducted immediately upon identification, as this can pave the way for surgical intervention.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Hubers SA, DeSimone DC, Gersh BJ, Anavekar NS: Infective endocarditis: a contemporary review. Mayo Clin Proc. 2020, 95:982-97. 10.1016/j.mayocp.2019.12.008
2. Vincent LL, Otto CM: Infective endocarditis: update on epidemiology, outcomes, and management. Curr Cardiol Rep. 2018, 20:86. 10.1007/s11886-018-1045-2
3. Ludhwani D, Li J, Huang EE, Sikora A, Thomas G: Aerococcus urinae aortic valve endocarditis with kissing aortic wall ulcer: a case report and literature review. Am J Case Rep. 2020, 21:e920974. 10.1265/AJCR.920974
4. Murdoch DR, Corey GR, Hoen B, et al.: Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009, 169:463-73. 10.1001/archinternmed.2008.605
5. Yahab B, Kühnle J, Musci M, et al.: Aerococcus urinae – a potent biofilm builder in endocarditis. PLoS One. 2020, 15:e0231827. 10.1371/journal.pone.0231827
6. Wang A, Gaca IG, Chu VH: Management considerations in infective endocarditis: a review. JAMA. 2018, 320:72-83. 10.1001/jama.2018.7596
7. Durack DT, Lukes AS, Bright DK: New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med. 1994, 96:200-9. 10.1016/0002-9343(94)90145-0
8. Baddour LM, Wilson WR, Bayer AS, et al.: Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015, 131:1435-86. 10.1161/CIR.0000000000000296
9. Ebnöther C, Altwegg M, Gottschalk J, Seebach JD, Kronenberg A: Aerococcus urinae endocarditis: case report and review of the literature. Infect. 2002, 30:510-5. 10.1007/s15010-002-3106-x
10. Sous N, Piozo JA, Barr AZ, Bhavsar SM: Subacute Aerococcus urinae infective endocarditis with mycotic aneurysms in a pediatric patient: case report and literature review. JPediatric Infect Dis Soc. 2019, 8:492-4. 10.1093/jpids/puz016
11. Kotkar KD, Said SM, Michelelina H, Wanta B, Fritock MD, Baddour LM: Right coronary artery septic embolization secondary to Aerococcus urinae native mitral valve endocarditis. Ann Thorac Surg. 2016, 102:e295-7. 10.1016/j.athoracsur.2016.02.069
12. Yabes JM, Perdikis S, Graham DB, Markeza A: A rare case of Aerococcus urinae infective endocarditis in an atypically young male: case report and review of the literature. BMC Infect Dis. 2018, 18:522. 10.1186/s12879-018-5414-0
13. Otto CM, Nishimura RA, Bonow RO, et al.: 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2021. 143:e55-71. 10.1161/CIR.0000000000000952

14. Tai DB, Go JR, Fida M, Saleh OA: Management and treatment of Aerococcus bacteremia and endocarditis. Int J Infect Dis. 2021, 102:584-9. 10.1016/j.ijid.2020.10.096

15. Nishimura RA, Otto CM, Bonow RO, et al.: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2014, 148:e1-e132. 10.1016/j.jtcvs.2014.05.014

16. Feghaly J, Rivas Rios J, Ravi M, Sattiraju S, Missov E: Aerococcus urinae infective endocarditis. Cureus. 2022, 14:e23947. 10.7759/cureus.23947

17. Lattanzio N, Abdelal Q, Bell S, et al.: A case report of Aerococcus urinae prosthetic valve infective endocarditis initially misidentify. Int J Clin Cardiol. 7:184-10. 10.23937/2378-2951/1410184

18. Jaya D Bathina, Kasaiah Makam, Robin Horn, Sandra Weiss: Aerococcus urinae: a rare cause for multi-valve endocarditis. Am J Biomed Sci Res. 2019, 2:1. 10.34297/AJBSR.2019.02.000568

19. Rosborough K, Durafout BA, Chan W, Dejong P, Appireddy R: Aerococcus urinae endocarditis presenting with bilateral cerebellar infarcts. Can J Neurol Sci. 2020, 47:724-6. 10.1017/cjn.2020.80

20. Martín-Guerra JM, Martín-Asenjo M, Dueñas-Gutierrez CJ: Aerococcus urinae infective endocarditis. Enferm Infecc Microbiol Clin (Engl Ed). 2020, 38:452-3. 10.1016/j.eimc.2020.01.015

21. Ahmed Y, Bardia N, Judge C, Ahmad S, Malozzi C, Calderon E: Aerococcus urinae: a rare cause of endocarditis presenting with acute stroke. J Med Cases. 2021, 12:65-70. 10.14740/jmc3612

22. Varughese R, Mathew A, Chadha R, Kostka J, Regelmann D: Prosthetic valve endocarditis caused by Aerococcus urinae. IDEcases. 2020, 21:e69912. 10.1016/j.idcr.2020.e69912

23. Khan M, Gill H, Khan M, Saravanan V, Jha P: Urine my heart: a case of Aerococcal endocarditis. Cureus. 2021, 13:e14595. 10.7759/cureus.14595